Exposure to Oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 2, 2011, Pages 296-302

  Peltoniemi, M A ^a   Saari, T I ^a   Hagelberg, N M ^a   Reponen, P ^b   Turpeinen, M ^b   Laine, K ^a   Neuvonen, P J ^c   Olkkola, K T ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ITRACONAZOLE; KETAMINE; KETANEST; PLACEBO; TICLOPIDINE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; ANESTHETICS, DISSOCIATIVE; ANTIFUNGAL AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; ITRACONAZOLE; KETAMINE; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; YOUNG ADULT;

EID: 79960566939     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.140     Document Type: Article

References (46)

1. Fisher, K., Coderre, T.J. & Hagen, N.A. Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J. Pain Symptom Manage. 20, 358-373 (2000).
2. Visser, E. & Schug, S.A. The role of ketamine in pain management. Biomed. Pharmacother. 60, 341-348 (2006).
3. Blonk, M.I., Koder, B.G., van den Bemt, P.M. & Huygen, F.J. Use of oral ketamine in chronic pain management: a review. Eur. J. Pain 14, 466-472 (2010).
4. Arendt-Nielsen, L., Nielsen, J., Petersen-Felix, S., Schnider, T.W. & Zbinden, A.M. Effect of racemic mixture and the (S+)-isomer of ketamine on temporal and spatial summation of pain. Br. J. Anaesth. 77, 625-631 (1996). (Pubitemid 26385793)
5. Clements, J.A., Nimmo, W.S. & Grant, I.S. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J. Pharm. Sci. 71, 539-542 (1982). (Pubitemid 12063731)
6. Chong, C., Schug, S.A., Page-Sharp, M., Jenkins, B. & Ilett, K.F. Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: preliminary findings from a three-way randomized, crossover study. Clin. Drug Investig. 29, 317-324 (2009).
7. Kharasch, E.D. & Labroo, R. Metabolism of ketamine stereoisomers by human liver microsomes. Anesthesiology 77, 1201-1207 (1992). (Pubitemid 23001132)
8. Yanagihara, Y. et al. Involvement of CYP2B6 in n-demethylation of ketamine in human liver microsomes. Drug Metab. Dispos. 29, 887-890 (2001). (Pubitemid 32488646)
9. Portmann, S., Kwan, H.Y., Theurillat, R., Schmitz, A., Mevissen, M. & Thormann, W. Enantioselective capillary electrophoresis for identification and characterization of human cytochrome P450 enzymes which metabolize ketamine and norketamine in vitro. J. Chromatogr. A 1217, 7942-7948 (2010).
10. Lo, J.N. & Cumming, J.F. Interaction between sedative premedicants and ketamine in man in isolated perfused rat livers. Anesthesiology 43, 307-312 (1975).
11. Kpel, C., Arndt, I. & Ibe, K. Effects of enzyme induction, renal and cardiac function on ketamine plasma kinetics in patients with ketamine long-term analgosedation. Eur. J. Drug Metab. Pharmacokinet. 15, 259-263 (1990). (Pubitemid 20313127)
12. Hijazi, Y. & Boulieu, R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab. Dispos. 30, 853-858 (2002). (Pubitemid 34671099)
13. Hagelberg, N.M. et al. Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. Eur. J. Pain 14, 625-629 (2010).
14. Rodrigues, A.D., Roberts, E.M., Mulford, D.J., Yao, Y. & Ouellet, D. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily. Drug Metab. Dispos. 25, 623-630 (1997). (Pubitemid 27213105)
15. Gorski, J.C., Jones, D.R., Haehner-Daniels, B.D., Hamman, M.A., O'Mara, E.M. Jr & Hall, S.D. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther. 64, 133-143 (1998). (Pubitemid 28423848)
16. Walsky, R.L., Astuccio, A.V. & Obach, R.S. Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J. Clin. Pharmacol. 46, 1426-1438 (2006). (Pubitemid 44704203)
17. Olkkola, K.T., Backman, J.T. & Neuvonen, P.J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 55, 481-485 (1994). (Pubitemid 24192233)
18. Kaukonen, K.M., Olkkola, K.T. & Neuvonen, P.J. Itraconazole increases plasma concentrations of quinidine. Clin. Pharmacol. Ther. 62, 510-517 (1997). (Pubitemid 28214928)
19. Richter, T. et al. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J. Pharmacol. Exp. Ther. 308, 189-197 (2004). (Pubitemid 38090717)
20. Turpeinen, M., Raunio, H. & Pelkonen, O. The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Curr. Drug Metab. 7, 705-714 (2006). (Pubitemid 44509677)
21. Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J. & Raunio, H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch. Toxicol. 82, 667-715 (2008).
22. Bell, R.F. Ketamine for chronic non-cancer pain. Pain 141, 210-214 (2009).
23. Huge, V. et al. Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. Eur. J. Pain 14, 387-394 (2010).
24. Grant, I.S., Nimmo, W.S. & Clements, J.A. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br. J. Anaesth. 53, 805-810 (1981). (Pubitemid 11044337)
25. Ebert, B., Mikkelsen, S., Thorkildsen, C. & Borgbjerg, F.M. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur. J. Pharmacol. 333, 99-104 (1997). (Pubitemid 27380456)
26. Ha-Duong, N.T., Dijols, S., Macherey, A.C., Goldstein, J.A., Dansette, P.M. & Mansuy, D. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 40, 12112-12122 (2001). (Pubitemid 32946552)
27. Kot, M. & Daniel, W.A. Effect of diethyldithiocarbamate (DDC) and ticlopidine on CYP1A2 activity and caffeine metabolism: an in vitro comparative study with human cDNA-expressed CYP1A2 and liver microsomes. Pharmacol. Rep. 61, 1216-1220 (2009).
28. Turpeinen, M., Tolonen, A., Uusitalo, J., Jalonen, J., Pelkonen, O. & Laine, K. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin. Pharmacol. Ther. 77, 553-559 (2005). (Pubitemid 40824968)
29. Zanger, U.M., Klein, K., Saussele, T., Blievernicht, J., Hofmann, M.H. & Schwab, M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8, 743-759 (2007). (Pubitemid 47288975)
30. Zanger, U.M., Turpeinen, M., Klein, K. & Schwab, M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 392, 1093-1108 (2008).
31. Nivoix, Y., Levue, D., Herbrecht, R., Koffel, J.C., Beretz, L. & Ubeaud-Sequier, G. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin. Pharmacokinet. 47, 779-792 (2008).
32. Venkatakrishnan, K., von Moltke, L.L. & Greenblatt, D.J. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokinet. 38, 111-180 (2000). (Pubitemid 30122116)
33. S aari, T.I. et al. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone. Eur. J. Clin. Pharmacol. 66, 387-397 (2010).
34. Yasui-Furukori, N., Saito, M., Niioka, T., Inoue, Y., Sato, Y. & Kaneko, S. Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. Ther. Drug Monit. 29, 45-48 (2007). (Pubitemid 46279875)
35. Wang, E.J., Lew, K., Casciano, C.N., Clement, R.P. & Johnson, W.W. Interaction of common azole antifungals with P glycoprotein. Antimicrob. Agents Chemother. 46, 160-165 (2002). (Pubitemid 34031618)
36. Gupta, A., Unadkat, J.D. & Mao, Q. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP). J. Pharm. Sci. 96, 3226-3235 (2007).
37. Kivist K.T., Lamberg, T.S., Kantola, T. & Neuvonen, P.J. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin. Pharmacol. Ther. 62, 348-354 (1997). (Pubitemid 27417801)
38. Neuvonen, P.J. & Jalava, K.M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. 60, 54-61 (1996). (Pubitemid 26279221)
39. Geisslinger, G., Hering, W., Thomann, P., Knoll, R., Kamp, H.D. & Brune, K. Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br. J. Anaesth. 70, 666-671 (1993). (Pubitemid 23169062)
40. Michna, E. et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J. Pain Symptom Manage. 28, 250-258 (2004). (Pubitemid 39158807)
41. Feng, N., Vollenweider, F.X., Minder, E.I., Rentsch, K., Grampp, T. & Vonderschmitt, D.J. Development of a gas chromatography-mass spectrometry method for determination of ketamine in plasma and its application to human samples. Ther. Drug Monit. 17, 95-100 (1995).
42. Compas, D., Touw, D.J. & de Goede, P.N. Rapid method for the analysis of itraconazole and hydroxyitraconazole in serum by high-performance liquid chromatography. J. Chromatogr. B, Biomed. Appl. 687, 453-456 (1996). (Pubitemid 27046553)
43. Gubbins, P.O., Gurley, B.J. & Bowman, J. Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum. J. Pharm. Biomed. Anal. 16, 1005-1012 (1998). (Pubitemid 28139037)
44. Bond, A. & Lader, M. The use of analogue scales in rating subjective feelings. Br. J. Med. Psychol. 47, 211-218 (1974).
45. Hannington-Kiff, J.G. Measurement of recovery from outpatient general anaesthesia with a simple ocular test. Br. Med. J. 3, 132-135 (1970).
46. Stone, B.M. Pencil and paper tests-sensitivity to psychotropic drugs. Br. J. Clin. Pharmacol. 18 (suppl. 1), 15S-20S (1984). (Pubitemid 15184100)